Weill Cornell Medicine

Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

Retrieved on: 
水曜日, 5月 22, 2024
Biotechnology, Pharmaceutical, Health, Neurology, PwC, Patient, Atalanta, University, RNA interference, CFO, FTD, IND, Therapy, Drug development, Weill Cornell Medical Center, DSM-IV codes, Weill Cornell Medicine, Growth, Research, NewYork-Presbyterian Hospital, CNS, Chemical engineering, Accounting, RNA, Frontotemporal dementia, Georgetown University, Pharmaceutical industry

Atalanta Therapeutics , a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the expansion of its executive team with the appointments of Serena Hung, M.D., as chief medical officer, and Jeffrey Young as chief financial officer.

Key Points: 
  • Atalanta Therapeutics , a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the expansion of its executive team with the appointments of Serena Hung, M.D., as chief medical officer, and Jeffrey Young as chief financial officer.
  • “We are thrilled to welcome Jeffrey and Serena to Atalanta’s executive team as we prepare for our next phase of growth in building the leading CNS RNAi company,” said Alicia Secor, Atalanta’s president and chief executive officer.
  • “Atalanta’s discovery efforts utilize our best-in-class di-siRNA platform and have generated a robust portfolio of 14 current programs across our wholly-owned and partnered pipelines.
  • Mr. Young joins Atalanta with more than 25 years of experience in finance and capital markets at life sciences and medical technology companies.

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Weill Cornell Medicine, FTD, Fast Track, Cohort, Natural history, Public expenditure, Cornell University, Patient, Treatment, FA, Intellectual property, Therapy, Orphan drug, G&A, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported first quarter 2024 financial results and provided operational highlights.

Key Points: 
  • Additionally, in April 2024, the FDA granted Fast Track designation (FTD) to LX2006, which Lexeo expects will facilitate its clinical development.
  • Closed $95 Million PIPE Financing: In March 2024, Lexeo announced the closing of an oversubscribed $95 million equity financing.
  • Lexeo anticipates that current cash, cash equivalents and marketable securities will be sufficient to fund operating and capital expenditures into 2027.
  • Cash Position: As of March 31, 2024, cash and cash equivalents were $195.1 million, which we believe will be sufficient to fund operations into 2027.

Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors

Retrieved on: 
水曜日, 5月 8, 2024
Brandeis University, Weill Cornell Medicine, Public health, Woman, Health, Johnson & Johnson, Private practice, Cambia Health Solutions, Pfizer, Patient, Boston Scientific, BSX, American Heart Association

MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.

Key Points: 
  • MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
  • Prior to that, Dr. Pegus was executive vice president of Health & Wellness at Walmart, president of Consumer Solutions and chief medical officer for Cambia Health Solutions and chief medical officer at Walgreens.
  • Dr. Pegus began her career in private practice as a cardiologist and previously served as board chair for the Association of Black Cardiologists.
  • "We are pleased to expand our board of directors with a highly respected, visionary clinical leader," said Mike Mahoney, chief executive and chairman of the board, Boston Scientific.

Albert Einstein College of Medicine Names Yoon Kang, M.D., Vice Dean for Education

Retrieved on: 
火曜日, 5月 7, 2024
Weill Cornell Medicine, University, Economics, Marilyn, MSTP, Curriculum, Ruth, Accreditation, Physician, College, Faculty, AAMC, Student, Albert Einstein, Barnes-Jewish Hospital, Strategic planning, Nursing

BRONX, N.Y., May 7, 2024 /PRNewswire/ -- Albert Einstein College of Medicine has appointed nationally recognized education leader Yoon Kang, M.D., as its inaugural vice dean for education, following a national search.

Key Points: 
  • BRONX, N.Y., May 7, 2024 /PRNewswire/ -- Albert Einstein College of Medicine has appointed nationally recognized education leader Yoon Kang, M.D., as its inaugural vice dean for education, following a national search.
  • Dr. Kang is currently the senior associate dean for education at Weill Cornell Medicine, where she has overseen all undergraduate medical education programs and offices, the office of continuing medical education, and recently the physician assistant program.
  • , The Marilyn and Stanley M. Katz Dean at Einstein and chief academic officer at Montefiore Einstein.
  • She will work closely with the College of Medicine's institutional and education leaders to implement the strategic plan for education currently in development.

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

Retrieved on: 
金曜日, 5月 3, 2024
Weill Cornell Medical Center, Hyperplasia, Weill Cornell Medicine, Patient, Neurocrine Biosciences, Clinical Pediatrics, CAH, Safety, GC, Androstenedione, Food, Male, Congenital adrenal hyperplasia, Observation, Obesity, Disease, D.O, Hirsutism, Diagnosis, Poster, Associate, Adrenocorticotropic hormone, Natural history, SAN, Pharmaceutical industry

SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.

Key Points: 
  • SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
  • These new data were presented at the Pediatric Endocrine Society 2024 Annual Meeting in Chicago.
  • Baseline characteristics of the subjects who enrolled in the CAHtalyst Pediatric Phase 3 study were presented (Poster# 56).
  • Neurocrine Biosciences also presented glucocorticoid treatment patterns from a recent cohort of pediatric and adult patients participating in the CAHtalog Registry (Poster# 51).

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

Retrieved on: 
水曜日, 5月 1, 2024
ECOG, NCCN, STS, Weill Cornell Medicine, Food, Professor, National Comprehensive Cancer Network, Orphan, MD, AML, ASH, Patient, Society, Virus, European Medicines Agency, Pharmaceutical industry

HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.

Key Points: 
  • Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We continue to be encouraged by the growing body of data Annamycin has demonstrated across our ongoing development programs.
  • As we continue on our pathway forward, we are pleased to bolster our Annamycin development programs with the formation of this Scientific Advisory Board and add the internationally-renowned knowledge and expertise of Dr. Tallman.
  • We are committed to advancing our clinical and regulatory strategies toward our next phase of development for Annamycin."
  • Dr. Tallman added, "The latest preliminary AML data suggest that Annamycin could result in a promising new the treatment for AML.

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Retrieved on: 
水曜日, 4月 24, 2024
Wilfrid Sellars, University, Mayo Clinic, Weill Cornell Medicine, University of Miami, Poster, BCT, MD, TSX, Principal investigator, Doctor of Philosophy, Spacecraft, UPMC, McCormick Place, DRS, ASCO, Cornell University, ADC, Patient, Society, Annual general meeting, Therapy, Partner, Pharmaceutical industry

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD

Key Points: 
  • Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
    Two poster presentations include Drs.
  • Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, will be giving the presentation.
  • BriaCell will also have two poster presentations.
  • The first poster will describe the Company’s ongoing pivotal Phase 3 registrational study in advanced metastatic breast cancer.

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Retrieved on: 
月曜日, 4月 22, 2024
FDA, Weill Cornell Medicine, Patient, Fast Track, Phenotype, Death, Cardiomyopathy, Research, Natural history, IND, Cornell University, Senior, Friedreich's ataxia, Cardiovascular disease, Therapy, Orphan drug, Pharmaceutical industry

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

Key Points: 
  • Under the license agreement, Lexeo has acquired certain rights1 including rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy ( NCT05302271 ).
  • The agreement will support Lexeo’s efforts to develop a potentially life-changing therapy for this unmet need.
  • Lexeo previously licensed know-how relating to AAVrh.10hFXN from Weill Cornell Medicine and collaborated with researchers there to further study the candidate, which Lexeo refers to as LX2006.
  • “This agreement with Lexeo Therapeutics builds upon years of collaboration between Weill Cornell Medicine and Lexeo to benefit patients with FA cardiomyopathy.

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
木曜日, 4月 18, 2024
FDA, University, RNA interference, Hospital, Hope, Safety, Survival, Weill Cornell Medicine, Holding, AML, Salvage therapy, Cornell University, D.O, MD Anderson Cancer Center, Patient, Clinical, Medicine, Acute myeloid leukemia, Messenger, Clinical trial, Scripps Health, BH3, Cancer, Pharmaceutical industry

By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.

Key Points: 
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 4月 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.